NO910923L - Trifunksjonell antistofflignende forbindelse som et kombinert diagnostisk og terapeutisk middel. - Google Patents

Trifunksjonell antistofflignende forbindelse som et kombinert diagnostisk og terapeutisk middel.

Info

Publication number
NO910923L
NO910923L NO91910923A NO910923A NO910923L NO 910923 L NO910923 L NO 910923L NO 91910923 A NO91910923 A NO 91910923A NO 910923 A NO910923 A NO 910923A NO 910923 L NO910923 L NO 910923L
Authority
NO
Norway
Prior art keywords
therapeutic agent
similar compound
trifunctional antibody
combined diagnostic
antibody similar
Prior art date
Application number
NO91910923A
Other languages
English (en)
Norwegian (no)
Other versions
NO910923D0 (no
Inventor
Clarence Ahlem
Ann E Huang
Original Assignee
Hybritech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybritech Inc filed Critical Hybritech Inc
Publication of NO910923D0 publication Critical patent/NO910923D0/no
Publication of NO910923L publication Critical patent/NO910923L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO91910923A 1990-03-09 1991-03-08 Trifunksjonell antistofflignende forbindelse som et kombinert diagnostisk og terapeutisk middel. NO910923L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49140690A 1990-03-09 1990-03-09

Publications (2)

Publication Number Publication Date
NO910923D0 NO910923D0 (no) 1991-03-08
NO910923L true NO910923L (no) 1991-09-10

Family

ID=23952086

Family Applications (1)

Application Number Title Priority Date Filing Date
NO91910923A NO910923L (no) 1990-03-09 1991-03-08 Trifunksjonell antistofflignende forbindelse som et kombinert diagnostisk og terapeutisk middel.

Country Status (7)

Country Link
EP (1) EP0453082A1 (fr)
JP (1) JPH0692873A (fr)
AU (1) AU637202B2 (fr)
CA (1) CA2037835A1 (fr)
IL (1) IL97459A0 (fr)
NO (1) NO910923L (fr)
ZA (1) ZA911741B (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5561220A (en) * 1991-02-08 1996-10-01 Diatech, Inc. Technetium-99m labeled peptides for imaging inflammation
US5736122A (en) * 1991-02-08 1998-04-07 Diatide, Inc. Technetium-99m labeled peptides for thrombus imaging
US5443815A (en) * 1991-11-27 1995-08-22 Diatech, Inc. Technetium-99m labeled peptides for imaging
US5552525A (en) * 1991-02-08 1996-09-03 Diatech Inc. Technetium-99m labeled peptides for imaging inflammation
US5645815A (en) 1991-02-08 1997-07-08 Diatide, Inc. Radiolabled compounds for thrombus imaging
US6019958A (en) * 1991-02-08 2000-02-01 Diatide, Inc. Technetium-99m labeled peptides for imaging inflammation
ATE188387T1 (de) * 1991-02-08 2000-01-15 Diatide Inc Technetium-99m markierte polypeptide zur bildformung
WO1993002105A1 (fr) * 1991-07-19 1993-02-04 Hybritech Incorporated Composes trifonctionnels presentant une specificite contre les cellules resistant a plusieurs medicaments____________________
WO1995000553A1 (fr) * 1993-06-23 1995-01-05 Diatech, Inc. Peptides radiomarques derives de la somatostatine et utilises dans des procedes d'imagerie et therapeutiques
US5989519A (en) * 1992-03-13 1999-11-23 Diatide, Inc. Technetium-99m labeled peptides for imaging inflammation
US5508020A (en) * 1992-06-05 1996-04-16 Diatech, Inc. Technetium-99M labeled peptides for imaging
DE69334033D1 (de) * 1992-05-21 2006-07-27 Diatide Inc Technetium-99M markierte Peptide zur Bilderzeugung von Thrombus
US5968476A (en) * 1992-05-21 1999-10-19 Diatide, Inc. Technetium-99m labeled peptides for thrombus imaging
US5871711A (en) * 1992-06-23 1999-02-16 Diatide, Inc. Radioactively-labeled somatostatin-derived peptides for imaging and therapeutic uses
US5716596A (en) * 1992-06-23 1998-02-10 Diatide, Inc. Radioactively labeled somatostatin-derived peptides for imaging and therapeutic uses
US6017512A (en) * 1992-06-23 2000-01-25 Diatide, Inc. Radiolabeled peptides
US5620675A (en) * 1992-06-23 1997-04-15 Diatech, Inc. Radioactive peptides
GB9221657D0 (en) * 1992-10-15 1992-11-25 Scotgen Ltd Recombinant bispecific antibodies
GB2286189A (en) * 1992-10-15 1995-08-09 Scotgen Ltd Recombinant specific binding protein
ZA942439B (en) * 1993-04-08 1996-01-08 Diatech Inc Radiolabeled compounds for thrombus imaging
US5951964A (en) * 1993-06-04 1999-09-14 Diatide, Inc. Technetium-99m labeled peptides for imaging
GB9314623D0 (en) 1993-07-14 1993-08-25 Nordion Int Inc Localization and therapy with agents directed against prostate specific antigen in breast cancer
US6051206A (en) * 1994-06-03 2000-04-18 Diatide, Inc Radiolabeled somatostatin-derived peptides for imaging and therapeutic uses
DK0912612T3 (da) * 1996-07-25 2004-02-02 Gsf Forschungszentrum Umwelt Forenklet fremstilling af bispecifikke antistoffragmenter
WO1999002567A2 (fr) * 1997-07-08 1999-01-21 Board Of Regents, The University Of Texas System Compositions et procedes destines a des homoconjugues d'anticorps qui induisent l'arret de la croissance ou l'apoptose de cellules tumorales
RU2149023C1 (ru) * 1998-04-20 2000-05-20 Ерхов Валентин Сергеевич Способ получения специфической антисыворотки к универсальному опухолевому антигену и способ диагностики злокачественных опухолей с использованием этой антисыворотки
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
EP1419786A1 (fr) 2002-11-13 2004-05-19 Bracco Imaging S.p.A. Méthode pour sélectivement et quantitativement fonctionnaliser des fragments Fab d'immunoglobuline, molécules conjuguées utilisant ceux-ci et ses compositions
US8921528B2 (en) 2004-06-01 2014-12-30 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
EP2674440B1 (fr) 2005-12-16 2019-07-03 IBC Pharmaceuticals, Inc. Ensembles bioactifs à base d'immunoglobuline multivalent
EP3243527B1 (fr) 2009-02-13 2019-06-05 Immunomedics, Inc. Immunoconjugués comportant une liaison clivable au niveau intracellulaire
WO2017004144A1 (fr) 2015-07-01 2017-01-05 Immunomedics, Inc. Immunoconjugués d'anticorps sn-38 avec un lieur cl2a
AU2013360335B2 (en) 2012-12-13 2017-12-07 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
EP2961435B1 (fr) 2013-02-28 2019-05-01 ImmunoGen, Inc. Conjugués comprenant des agents de liaison cellulaire (cba) et des agents cytotoxiques
SI3204018T1 (sl) 2014-10-07 2021-11-30 Immunomedics, Inc. Neoadjuvantna uporaba konjugatov protitelo-zdravilo
AU2016281622C1 (en) 2015-06-25 2021-11-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
WO2017214151A1 (fr) 2016-06-06 2017-12-14 Northwestern University Construction de protéines de fusion
US12158399B2 (en) 2016-08-05 2024-12-03 Duke University CaMKK2 inhibitor compositions and methods of using the same
JOP20190100A1 (ar) 2016-11-19 2019-05-01 Potenza Therapeutics Inc بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
PL3658589T3 (pl) 2017-07-26 2024-03-18 Forty Seven, Inc. Przeciwciała anty-sirp-alfa i powiązane sposoby
JP7653013B2 (ja) 2018-01-04 2025-03-28 アイコニック セラピューティクス リミテッド ライアビリティ カンパニー 抗組織因子抗体、抗体薬物コンジュゲート、及び関連する方法
US12281171B2 (en) 2018-03-19 2025-04-22 Bio Ventures, Llc Periostin antibodies and methods of using the same
WO2019227022A1 (fr) 2018-05-25 2019-11-28 Bioventures, Llc Compositions de virus myxoma et procédés d'utilisation
WO2020106880A1 (fr) 2018-11-20 2020-05-28 Bioventures, Llc Cellules pour la production de virus et leurs procédés d'utilisation
WO2023028501A1 (fr) 2021-08-23 2023-03-02 Immunitas Therapeutics, Inc. Anticorps anti-cd161 et leurs utilisations
WO2025240781A2 (fr) 2024-05-15 2025-11-20 Werewolf Therapeutics, Inc. Anticorps modifiés et formats d'immunoglobuline
WO2026042013A1 (fr) 2024-08-19 2026-02-26 Institute Of Molecular And Clinical Ophthalmology Basel (Iob) Thérapie mitochondriale

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
CA1260827A (fr) * 1984-08-31 1989-09-26 Richard C. Siegel Complexes anticorps - ions metalliques
US4722892A (en) * 1984-08-31 1988-02-02 Meares Claude F Monoclonal antibodies against metal chelates
US4659839A (en) * 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
US4831122A (en) * 1986-01-09 1989-05-16 Regents Of The University Of Minnesota Radioimmunotoxins
IL84842A0 (en) * 1986-12-24 1988-06-30 Lilly Co Eli Immunoglobulin conjugates
US4814438A (en) * 1986-12-24 1989-03-21 Eli Lilly And Company Immunoglobulin conjugates of 2',2'-difluronucleosides
US5202451A (en) * 1988-02-17 1993-04-13 Neorx Corporation Anchimeric radiometal chelating compounds
FI105320B (fi) * 1988-04-04 2000-07-31 Oncogen Menetelmä vasta-aineheterokonjugaattien valmistamiseksi, joita käytetään imusoluaktiivisuuden säätelyssä ja diagnoosissa
GB8813527D0 (en) * 1988-06-08 1988-07-13 Glennie M J Bispecific antibodies
GB8824869D0 (en) * 1988-10-24 1988-11-30 Stevenson G T Synthetic antibody

Also Published As

Publication number Publication date
CA2037835A1 (fr) 1991-09-10
AU7272291A (en) 1991-09-12
JPH0692873A (ja) 1994-04-05
ZA911741B (en) 1992-11-25
EP0453082A1 (fr) 1991-10-23
AU637202B2 (en) 1993-05-20
IL97459A0 (en) 1992-06-21
NO910923D0 (no) 1991-03-08

Similar Documents

Publication Publication Date Title
NO910923D0 (no) Trifunksjonell antistofflignende forbindelse som et kombinert diagnostisk og terapeutisk middel.
FI910851A7 (fi) 3-arylkarbonyl-1h-indoler anvaendbara som terapeutiska aemnen.
MX9102473A (es) Agentes farmaceuticos.
FI914619A7 (fi) Hydroxylfunktionaliserade polyeteraminer som barriaerfoerpackning foer syrekaensliga materialer.
FI914796L (fi) Omaettade hydroxialkylkinolinsyror som leukotrienantagonister.
FI914596L (fi) Biaxialt orienterad polypropylenfolie avsedd som foerpackningsomslag.
FI884924L (fi) Humanimmuglobulin som producerats med hybrid-dna-teknik.
FI896138A0 (fi) Polyolpolyestrar som fuktighetsbarriaer foer livsmedel.
DE59100682D1 (de) Atemschutzmaske.
FI915357A0 (fi) Optisk bakskiva som foerbinder kretskort.
FI914004A0 (fi) Epoxifunktionella siloxanhartskopolymerer som loesgoeringsreglerande tillaeggsaemnen.
FI914797L (fi) Maettade hydroxialkylkinolinsyror som leukotrienantagonister.
DE3889062D1 (de) Monoklonaler Antikörper gegen humanen BCDF.
FI912468A0 (fi) Oxidantkaensliga och -okaensliga aromatiska estrar som inhibitorer foer humant neutrofilelastas.
FI910572A7 (fi) Regnmaetare med anordning som paovisar tilltaeppning.
FI915568A0 (fi) Polyamidhartskompositioner foer anvaendning som bindemedel foer laminerande tryckfaergshartser.
FI891865L (fi) Laekemedel som innehaoller azelastin med kontrollerad frigoering av det verksamma aemnet.
FI923367L (fi) Molekyler med antikroppkombinations- staellen som katalyserar hydrolysreaktioner.
FI914795L (fi) Hydroxialkylkinolinetersyror som leukotrienantagonister.
NO890096D0 (no) Pyrazol- og indozolpyridinaminer, en fremgangsmaate for fremstilling og anvendelse derav som medikamenter.
DE69100165D1 (de) Aufreissbarer versandsumschlag.
FI923486A0 (fi) Terapeutiska aemnen.
NO901169D0 (no) Azol-1-alkanamider som anti-arrytmiske midler og fremstilling derav.
DE59104786D1 (de) Patientenliegefläche.
FR2713479B1 (fr) Bassin médical.